Is an external review worth pursuing after two internal denials?

This is a United States plan; I appreciate the answer is jurisdiction-specific.

I would like to set this up properly once, rather than adjust it repeatedly.

My budget is real but not tight, and my tolerance for uncertainty is low.

What should I decide now, and what should I defer?

The salt-versus-base issue is worth understanding precisely because it is a genuine regulatory tell rather than a technicality.

503A and 503B differ in what they are permitted to do and what they must demonstrate. A 503A pharmacy compounds against individual prescriptions, is exempt from current good manufacturing practice requirements, and is regulated primarily at state level with USP chapter compliance as the operative standard. A 503B outsourcing facility registers federally, must comply with cGMP, may prepare without patient-specific prescriptions, and is subject to FDA inspection. The practical consequence is that a 503B preparation carries release testing and a 503A preparation generally does not.

To be exact about it, a beyond-use date for a compounded multi-dose preparation is set under USP chapter provisions on the basis of microbiological risk category and, where available, supporting stability data. In practice most beyond-use dates in this space are default values from the risk-category table rather than the output of a stability study, and the two should not be read as equivalent claims.

Accreditation by the Pharmacy Compounding Accreditation Board or by ACHC is voluntary and verifiable, and verification is a matter of checking the accreditor’s register rather than accepting a logo on a website.

The caveat is jurisdictional. Almost everything in this area is specific to a country and often to a sub-national jurisdiction, and a confident answer that does not name a jurisdiction should be treated as describing somewhere else.

If the intake did not ask about contraindications, that tells you what kind of service it is.

edited 19 May 2026 by unit_math — added the citation requested in comments

In practice, potency variation between compounders is a manufacturing-control question rather than an integrity question, and it is the predictable consequence of preparing a potent peptide by hand at small scale.

The salt-form point: the statutory pathway for compounding a copy of an approved drug during a shortage applies to the same active moiety as the approved product. A preparation described as a salt form — "semaglutide sodium", "semaglutide acetate" — is describing a different chemical entity from the approved base, and the description is usually there to construct an argument that it is not a copy. Whatever the legal merits, it means what is in the vial is not what was studied.

Denials come in two flavours and it is worth identifying which you have. A criteria denial means the submission did not evidence something the criteria require, and it is fixed by supplying the evidence. A formulary exclusion means the plan does not cover the drug at any level for any indication, and no amount of clinical documentation changes it — the route there is a formulary exception request or an employer-level appeal.

I would flag that a compounded preparation and an approved product are different objects even when they nominally contain the same molecule, and the difference is release testing rather than intent.

Keep every document. The appeal you might need in six months is built from records you have to have kept now.

Specifically, a defensible telehealth encounter has identifiable features, and the absence of those features is the most useful signal available to a prospective patient.

What a payer wants in a prior authorisation is documentation mapped to their own written criteria, in their own terms: a diagnosis code, a documented body mass index or comorbidity meeting their threshold, a record of a supervised lifestyle intervention over their specified duration, and documentation of any step-therapy agent tried and its outcome. A clinical narrative that does not map onto those fields will be denied by someone who never reads the narrative.

External review of health-plan denials in the United States operates under the Affordable Care Act’s appeal provisions and, for employer self-funded plans, under ERISA; the practical significance is that an independent reviewer applies the plan’s own criteria without the plan’s involvement.

Ask for the written criteria before you submit. Everything else in the process is easier once you have them.

The part that matters: model the cost across the whole route, including the parts that are not the drug: consultation fees, laboratory monitoring, shipping, and the tests you will pay for yourself.

Features of a defensible telehealth intake: a real history including contraindications and family history, a recorded weight and height rather than a self-attested figure, baseline laboratory work or a documented reason for its absence, a named prescriber you can identify and verify, a titration plan, and a mechanism for reporting adverse events that reaches a clinician. A checkbox intake that issues a prescription in four minutes has none of these.

Worth noting that regulatory status in this area has changed repeatedly over the past three years, so any answer including a date should be checked against the current position.

Verify accreditation on the accreditor’s register rather than on the pharmacy’s website. It takes a minute.

edited 28 Jul 2026 by aine_mulcahy — reworded for clarity after a comment